Siemens’ PETNET Solutions has entered into an agreement with U.K.-based Blue Earth Diagnostics to secure exclusive commercial manufacturing and distribution of fluciclovine (18F), an investigational PET radiopharmaceutical, once the agent receives FDA approval.
Fluciclovine (18F) is currently being studied for prostate imaging in clinical trials conducted in the U.S., Japan, Italy, Norway, Sweden, and Finland. The agent has a 110 minute half-life, and Siemens’ PETNET Solutions will facilitate the geographical distribution of the agent to clinical trial sites in the U.S. and then clinical imaging centers upon getting the green light from the FDA, according to the companies.
Blue Earth Diagnostics is a private diagnostic company formed last year with £12.8 million investment ($20 million USD) from Syncona Partners, a subsidiary of the Wellcome Trust. The company licensed fluciclovine (18F), also known as FACBC, from GE Healthcare.